Fennec Pharmaceuticals (FENC) Misses Q2 EPS by 7c

Fennec Pharmaceuticals (NASDAQ: FENC) reported Q2 EPS of ($0.11), $0.07 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $9.65 million versus the consensus estimate of $9.39 million.

For earnings history and earnings-related data on Fennec Pharmaceuticals (FENC) click here.

You May Also Be Interested In

• Corpay (CPAY) PT Raised to $480 at Cantor Fitzgerald
• EMCOR Group (EME) PT Lowered to $1,047 at Cantor Fitzgerald
• Fidelity National Information Services (FIS) PT Lowered to $50 at Cantor Fitzgerald